Senseonics (NYSE:SENS) said yesterday that it inked a non-exclusive R&D license agreement with TypeZero Technologies to develop artificial pancreas and decision support systems for its Eversense continuous glucose monitor.
The companies plan to integrate glucose readings from the Eversense system with TypeZero’s inControl artificial pancreas algorithms to regulate insulin delivery through a user’s insulin pump. The integration will also allow TypeZero’s decision support system to recommend basal and bolus doses for insulin pen users.
The deal is the 1st effort to combine a 90-day CGM sensor with smart algorithms for closed loop and decision support applications, the companies reported.
“We’re thrilled to partner with TypeZero with the goal of progressing the diabetes management field in providing solutions to help minimize the burden of diabetes for millions of people,” Senseonics’ president & CEO Tim Goodnow said in prepared remarks. “It is particularly gratifying that the combined Eversense and inControl platform is intended to be used by either insulin pumpers or insulin pen users. The continuous long-term use of an accurate sensor such as Eversense combined with the clinically proven treatment algorithms of inControl has the promise of impacting both pump and pen users in a positive and meaningful way.”
“We see the combination of our inControl technology with Senseonics’ sensor as potentially a huge win for persons with diabetes,” TypeZero CEO Chad Rogers added. “In many ways CGM data is the heartbeat of our artificial pancreas and decision support technologies, and integrating our inControl platform with the reliable and durable Eversense CGM System which could give patients yet another tool for managing their health and simplifying their lives.”
